Spring Capital Announces the Closing of its Fourth Fund
Spring Capital is pleased to announce the closing of Spring Capital Partners IV, L.P. (“SCP IV” or the “Fund”), a $250 million fund focused on making subordinated debt and minority equity investments in privately-held middle market businesses. Since its founding in 1999, Spring Capital has managed over $600 million in junior capital funds. “With the […]Read more
Paragon Bioservices Inc.
Headquartered in Baltimore MD, Paragon Bioservices is an industry-leading, contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon partners with the world’s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and […]Read more
Spring Capital invests in a broad range of industries with a geographic focus on companies and equity sponsors located in the eastern half of the United States.